ReviewNutrients2020
Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed.
Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception-A Systematic Review.Frontiers in neurology · 2020Pooled it
- Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial.Inflammopharmacology · 2023Trial
- Dose assessment of melatonin in sepsis (DAMSEL2) study: Pharmacokinetics of two doses of oral melatonin in patients with sepsis.Journal of pineal research · 2022Trial
- Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial.Journal of medical virology · 2022Trial
- Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.Archives of medical research · 2022Trial
- Melatonin and the Skin: Current Progress and Perspectives for Human Health.The Journal of investigative dermatology · 2025Review
- Melatonin protects against sarcopenia in middle-aged mice.Histology and histopathology · 2025Article
- Melatonin's Impact on Cytokine Storm and Modulation of Purinergic Receptors for COVID-19 Prognosis: A Mental Health Perspective.Journal of molecular neuroscience : MN · 2024Review
- Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.Journal of translational medicine · 2024Article
- Investigating the Effectiveness of Melatonin in the Treatment of Critically Ill Patients with COVID-19 Hospitalized in the Intensive Care Unit: A Double-Blind Randomized Clinical Trial.Medical journal of the Islamic Republic of Iran · 2024Article
- Review
- Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.Life sciences · 2022Review
- Article
- Dose-Dependent Effect of Melatonin on BAT Thermogenesis in Zücker Diabetic Fatty Rat: Future Clinical Implications for Obesity.Antioxidants (Basel, Switzerland) · 2022Article
- Nestin-dependent mitochondria-ER contacts define stem Leydig cell differentiation to attenuate male reproductive ageing.Nature communications · 2022Article
- Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia.Biomedicines · 2022Review
- Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.Molecular and cellular biochemistry · 2022Review
- Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022Review
- Phytomelatonin: a potential phytotherapeutic intervention on COVID-19-exposed individuals.Microbes and infection · 2022Review
- Tryptophan and Biogenic Amines in the Differentiation and Quality of Honey.International journal of tryptophan research : IJTR · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response contribute to COVID-19 pathology; these are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This leads to a cytokine storm and subsequent progression triggering acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and often death. We and others have reported melatonin to be an anti-inflammatory and anti-oxidative molecule with a high safety profile. It is effective in critical care patients by reducing their vascular permeability and anxiety, inducing sedation, and improving their quality of sleep. As melatonin shows no harmful adverse effects in humans, it is imperative to introduce this indoleamine into clinical trials where it might be beneficial for better clinical outcomes as an adjuvant treatment of COVID-19-infected patients. Herein, we strongly encourage health care professionals to test the potential of melatonin for targeting the COVID-19 pandemic. This is urgent, since there is no reliable treatment for this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.